Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor that has evidence of metastatic spread (stage IV) or is locally advanced and unresectable * Patients with breast cancer may have estrogen receptor positive or negative (ER+ or ER-) disease * Patients with breast cancer may not be human epidermal growth receptor -2 (HER2)-positive ( 3+), or fluorescent in situ hybridization (FISH) ratio \> 2.2 * Patients in the biopsy expansion cohort must have "triple negative" breast cancer defined as: * Estrogen receptor staining \< 10%; progesterone receptor staining \<10%; Her 2 \< 2.2 by FISH, or immunohistochemistry (IHC) 0-2+ * Patients may have been previously treated * In the dose escalation cohort, there is no limit to prior therapies * In the expansion cohort, patients may have only had 1-3 prior regimens for metastatic disease * Patients may have received prior carboplatin, paclitaxel, or poly (ADP-ribose) polymerase (PARP) inhibitor therapy as part of their previous treatment regimens * However, patients may NOT have received prior therapy with paclitaxel, carboplatin, and PARP inhibitor in combination * Patients must not have received chemotherapy within 4 weeks of starting study (or 6 weeks if prior treatment was with carmustine \[BCNU\] or mitomycin C) * Patients must not have received radiation within 2 weeks of starting study * Eastern Cooperative Oncology Group (ECOG) performance status (PS)\< 2 (Karnofsky \> 60%) * Life…